Similar articles

• Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis.

  Millar AD, Rampton DS, Chander CL, Claxson AW, Blades S, Coumbe A, Panetta J, Morris CJ, Blake DR. Millar AD, et al. Gut. 1996 Sep;39(3):407-15. doi: 10.1136/gut.39.3.407. Gut. 1996. PMID: 8949646 Free PMC article.
• Eicosanoid production by the mucosa in inflammatory bowel disease after 5-ASA treatment.

  Zijlstra FJ, van Dijk AP, Ouwendijk RJ, van Riemsdijk-Overbeeke IC, Wilson JH. Zijlstra FJ, et al. Agents Actions. 1993;38 Spec No:C122-4. doi: 10.1007/BF01991158. Agents Actions. 1993. PMID: 8317305
• The rectal approach to treatment in distal ulcerative colitis.

  Anderson FH. Anderson FH. Lancet. 1995 Aug 26;346(8974):520-1. doi: 10.1016/s0140-6736(95)91377-7. Lancet. 1995. PMID: 7658775 No abstract available.
• Mechanism of action of 5-aminosalicylic acid and its derivatives.

  Ireland A, Jewell DP. Ireland A, et al. Clin Sci (Lond). 1990 Feb;78(2):119-25. doi: 10.1042/cs0780119. Clin Sci (Lond). 1990. PMID: 2155736 Review.
• [New developments in therapy with 5-aminosalicylic acid preparations in ulcerative colitis and Crohn disease].

  Kruis W. Kruis W. Z Gastroenterol Verh. 1991 Mar;26:154-6. Z Gastroenterol Verh. 1991. PMID: 1714132 Review. German. No abstract available.